Carl read the papersWhat it actually is
Argireline is Lipotec's trade name for acetyl hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2). A Spanish team designed it to copy the N-terminal end of SNAP-25, one of the proteins a nerve uses to release the signal that makes a muscle contract, and published it in 2002. Some papers call it acetyl hexapeptide-3.
It is a topical cosmetic ingredient, made for serums and creams over expression lines, not for injection. Snap-8, which has its own page in this guide, works on the same target.
How it’s thought to work
- SNARE interference — Competes with SNAP-25 for a place in the SNARE complex, the machinery that releases acetylcholine where nerve meets muscle.
- Weaker micro-contractions — Less signal means slightly weaker contraction of the small facial muscles that crease expression lines.
- Potency vs efficacy — In the original lab work it blocked release with similar potency to Botox A but far lower efficacy. Same target, much softer hit.
- The skin barrier problem — In an FDA lab test on donated human skin, most of it washed off the surface: about 0.22% of the dose stayed in the outer skin layer, 0.01% reached the epidermis and none reached the dermis.
What the research says
Small but real. The original 2002 study, by the team that designed it, reported wrinkle depth down by up to 30% after 30 days. A 2013 Chinese randomised trial of 60 people scored 48.9% 'anti-wrinkle efficacy' against 0% for placebo after 4 weeks of twice-daily use, with skin roughness improved on silicone replicas; the same trial appears in two 2013 papers. On the other side, an NIH trial adding an Argireline cream to Botox injections for eyelid spasm found only a trend (3.7 vs 3.0 months before symptoms returned), and the NIH's own follow-up trial record says that dose was not very effective. A 70-person Thai trial of a 10% Argireline gel finished in 2009 and never posted results.
- Patterned on the N-terminal end of SNAP-25; interferes with SNARE complex formation.
- 2002 study by its designers: wrinkle depth down up to 30% at 30 days.
- 2013 randomised trial, n=60, 4 weeks twice daily: 48.9% subjective efficacy vs 0% placebo.
- FDA lab: about 0.01% of an applied dose reached the epidermis and none the dermis.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Trial strength | 0.005% actual peptide in the NIH cream, applied twice daily. The US Cosmetic Ingredient Review panel has only judged it safe up to 0.005% |
| Label percentages | Argireline is sold to formulators as a ready-made solution, mostly water, to be added at 2 to 10% of a product. So '10%' on a label most likely means 10% of that solution, not 10% pure peptide |
| Frequency | Twice daily to clean skin, as in the trials |
| Timeline | 4 weeks in the Chinese trial, 30 days in the original study, before judging anything |
| Route | Topical only |
| Carl's note | Do not inject it. There is a published case of a serious mycobacterial infection after Argireline injections into the forehead and temples. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Expression lines (crow's feet, forehead) | topical, twice daily, judged at 4 weeks or later |
| Alongside Snap-8 | same target; no trial of the pair |
| What it will not do | static wrinkles, volume loss, or anything close to injected Botox |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
You do not inject this one. Argireline is a cosmetic ingredient made for creams and serums, applied twice daily over expression lines. The peptide strength in real use is tiny: the NIH trial cream was 0.005%, which is also where the US safety panel's sign-off stops. Injecting cosmetic-grade peptide is how people end up in case reports, including a 45-year-old woman who needed five months of antibiotics for a mycobacterial infection after forehead and temple injections. If you want the injected version of this effect, that is botulinum toxin from a qualified injector.
Stacks it appears in
- With Snap-8 — Works on the same nerve-to-muscle signal. No trial has tested the two together.
- With Matrixyl — Different jobs: Argireline on muscle signalling, Matrixyl on collagen signalling. A small 2023 trial (21 women across three groups) ran them head to head, and Matrixyl came out ahead.
- With GHK-Cu — Different jobs: one on nerve signalling, one on repair. No trial of the combination.
Sources
- Blanes-Mira et al. 2002, Int J Cosmet Sci: A synthetic hexapeptide (Argireline) with antiwrinkle activity
- Wang et al. 2013, Am J Clin Dermatol: Argireline in Chinese subjects, randomised placebo-controlled
- Wang et al. 2013, J Cosmet Laser Ther: same 60-subject trial plus mouse study
- Kraeling et al. 2015, Cutan Ocul Toxicol (US FDA): In vitro skin penetration of acetyl hexapeptide-8
- Lungu et al. 2013, Eur J Neurol (NINDS): Topical AH8 for blepharospasm
- ClinicalTrials.gov NCT00942851 and NCT01750346 (NINDS acetyl hexapeptide-8 blepharospasm trials)
- ClinicalTrials.gov NCT01381484: Topical Argireline for periorbital wrinkles (Mahidol University)
- Johnson et al. 2025, Int J Toxicol (CIR Expert Panel): Safety assessment of acetyl hexapeptide-8 amide
- Chen et al. 2021, World J Clin Cases: Mycobacterium abscessus infection after facial injection of argireline
- Aruan et al. 2023, J Clin Aesthet Dermatol: Acetylhexapeptide-3 vs palmitoyl pentapeptide-4 creams for crow's feet
- Lotioncrafter: Argireline peptide solution NP (Lipotec) product page
- SAHPRA: Peptide Products - Public Information (May 2026)
